Synergy Pharmaceuticals (SGYP) Shares are Up 13.93%

Synergy Pharmaceuticals (SGYP) : Traders are bullish on Synergy Pharmaceuticals (SGYP) as it has outperformed the S&P 500 by a wide margin of 10.19% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 13.33%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 13.93% in the last 1 week, and is up 7.96% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 12.13% and the 50-Day Moving Average is 22.61%.The 200 Day SMA reached 37.8% Synergy Pharmaceuticals, Inc. is up 52.33% in the last 3-month period. Year-to-Date the stock performance stands at -1.94%.


Synergy Pharmaceuticals (SGYP) : The consensus price target for Synergy Pharmaceuticals (SGYP) is $10.75 for the short term with a standard deviation of $6.01. The most optimist securities analyst among the 2 who monitor the stock believes that the stock can reach $15, however, the pessimist price target for the company is $7.

For the current week, the company shares have a recommendation consensus of Buy. Synergy Pharmaceuticals (NASDAQ:SGYP): stock was range-bound between the intraday low of $5.45 and the intraday high of $5.9 after having opened at $5.9 on Fridays session. The stock finally closed in the red at $5.9, a loss of -4.63%. The stock remained in the red for the whole trading day. The total traded volume was 9,796,248 shares. The stock failed to cross $5.9 in Fridays trading. The stocks closing price on Thursday was $5.56.

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Companys platform technology is based on the naturally occurring human GI peptide, uroguanylin, a regulator of normal GI physiology. The Companys products include plecanatide, SP-333 and FV-100. The Companys lead product is plecanatide, a guanylate cyclase C (GC-C), receptor agonist, designed to treat GI disorders, primarily chronic idiopathic constipation (CIC), and constipation predominant irritable bowel syndrome (IBS-C). The Company is developing a second-generation GC-C receptor agonist, SP-333, for the treatment of opioid induced constipation (OIC), and for inflammatory bowel disease (IBD). FV-100 is an orally available nucleoside analog. The Companys subsidiaries include Synergy Advanced Pharmaceuticals, Inc., IgX, Ltd and ContraVir Pharmaceuticals, Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.